US Stock MarketDetailed Quotes

SLN Silence Therapeutics

Watchlist

21.130
+0.470+2.27%

Trading Apr 16 12:14 ET

984.98MMarket Cap-14552P/E (TTM)

Silence Therapeutics Stock Forum

Moomoo AI

Feb 3 20:08

Despite strong growth, Silence Therapeutics' high P/S ratio and weak revenue outlook suggest a risk of share price decline. Analysts lack confidence in a business turnaround, indicating potential risk for shareholders and potential investors.

Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking

Moomoo AI

Nov 27, 2023 18:17

Analysts' confidence appears low for Silence Therapeutics' business turnaround. The high P/S ratio and expected revenue decline suggest unsustainable current price levels which may erode current sentiment towards the stock.

Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 65% But Growth Is Lacking

Trytosaveabit

Nov 1, 2023 19:13

News

$Silence Therapeutics(SLN.US)$ Silence Therapeutics Reports Topline Results From Phase 1 Multiple Dose Study Of Zerlasiran; Lp(a) Levels Remained Around 90% Lower Than Baseline At Study Endpoint